• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Blueprint Medicines Corporation

    2/13/25 5:15:29 PM ET
    $BPMC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BPMC alert in real time by email
    S-8 1 tmb-20250213xs8.htm S-8

    As filed with the Securities and Exchange Commission on February 13, 2025

    Registration No. 333-        

    ​

    ​

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    ​


    FORM S-8

    REGISTRATION STATEMENT

    UNDER THE

    SECURITIES ACT OF 1933

    ​


    ​

    Blueprint Medicines Corporation

    (Exact name of registrant as specified in its charter)

    ​


    ​

    Delaware

     

    26-3632015

    (State or other jurisdiction

    of incorporation)

     

    (I.R.S. Employer
    Identification No.)

    ​

    ​

    ​

    45 Sidney Street

    Cambridge, Massachusetts

     

    02139

    (Address of principal executive offices)

     

    (Zip Code)

    ​

    2015 Employee Stock Purchase Plan

    (Full titles of the plans)

    ​

    Kathryn Haviland

    President and Chief Executive Officer

    Blueprint Medicines Corporation

    45 Sidney Street

    Cambridge, Massachusetts 02139

    (Name and address of agent for service)

    (617) 374-7580

    (Telephone number, including area code, of agent for service)

    Please send copies of all communications to:

    Kingsley L. Taft, Esq.

    Danielle M. Lauzon, Esq.

    Yasin Akbari, Esq.

    Goodwin Procter LLP

    100 Northern Avenue

    Boston, Massachusetts 02210

    (617) 570-1000


    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act.

    Large accelerated filer þ

    Non-accelerated filer  ◻

    ​

    Accelerated filer ◻

    Smaller reporting company  ◻

    Emerging growth company  ◻

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.◻


    ​


    EXPLANATORY NOTE

    ​

    This Registration Statement on Form S-8 relating to the 2015 Stock Option and Incentive Plan the 2015 Employee Stock Purchase Plan (as amended, the “2015 ESPP”) of Blueprint Medicines Corporation (the “Registrant”) is being filed for the purpose of registering additional securities of the same class as other securities for which a Registration Statement on Form S-8 has previously been filed and is effective. Accordingly, this Registration Statement on Form S-8 incorporates by reference the contents of (i) the Registration Statement on Form S-8 (File No. 333-203749) filed with the Securities and Exchange Commission (the “SEC”) on April 30, 2015 by the Registrant, relating to the 2015 ESPP, (ii) the Registration Statement on Form S-8 (File No. 333-210125) filed with the SEC on March 11, 2016 by the Registrant, relating to the 2015 ESPP, (iii) the Registration Statement on Form S-8 (File No. 333-216575) filed with the SEC on March 9, 2017 by the Registrant, relating to the 2015 ESPP, (iv) the Registration Statement on Form S-8 (File No. 333-223131) filed with the SEC on February 21, 2018 by the Registrant, relating to the 2015 ESPP, (v) the Registration Statement on Form S-8 (File No. 333-229885) filed with the SEC on February 26, 2019 by the Registrant, relating to the 2015 ESPP, (vi) the Registration Statement on Form S-8 (File No. 333-236421) filed with the SEC on February 13, 2020 by the Registrant, relating to the 2015 ESPP, (vii) the Registration Statement on Form S-8 (File No. 333-253215) filed with the SEC on February 17, 2021 by the Registrant, relating to the 2015 ESPP, (viii) the Registration Statement on Form S-8 (File No. 333-262800) filed with the SEC on February 17, 2022 by the Registrant, relating to the 2015 ESPP, (ix) the Registration Statement on Form S-8 (File No. 333-269844) filed with the SEC on February 17, 2023 by the Registrant, and (x) the Registration Statement on Form S-8 (File No. 333-280405) filed with the SEC on February 16, 2024,  in each case, except for “Item 8. Exhibits” with respect to which the Exhibit Index set forth below is incorporated herein by reference. 

    ​

    EXHIBIT INDEX

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    Incorporated by Reference

    ​

    ​

    ​

    Exhibit
    Number

    Description of Exhibit

    ​

    Form

    ​

    File No.

    ​

    Exhibit Number

    ​

    Filing Date

    ​

    3.1

    ​

    Fifth Amended and Restated Certificate of Incorporation of the Registrant

    ​

    10-Q

    ​

    001-37359

    ​

    3.1

    ​

    November 9, 2015

    ​

    3.2

    ​

    Amended and Restated Bylaws, as amended on November 30, 2022, of the Registrant

    ​

    8-K

    ​

    001-37359

    ​

    3.1

    ​

    December 6, 2022

    ​

    4.1

    ​

    Specimen Common Stock Certificate

    ​

    S-1/A

    ​

    333-202938

    ​

    4.1

    ​

    April 20, 2015

    ​

    5.1

    ​

    Opinion of Goodwin Procter LLP, counsel to the Registrant

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    *

    ​

    23.1

    ​

    Consent of Ernst & Young LLP, an independent registered public accounting firm

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    *

    ​

    23.2

    ​

    Consent of Goodwin Procter LLP (included in Exhibit 5.1)

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    *

    ​

    24.1

    ​

    Power of attorney (included on the signature pages of this registration statement)

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    *

    ​

    99.1

    ​

    2015 Employee Stock Purchase Plan

    ​

    10-K

    ​

    001-37359

    ​

    10.3

    ​

    February 13, 2020

    ​

    107

    ​

    Filing Fee Exhibit

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    *

    ​


    *   Filed herewith.

    ​


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Cambridge, Commonwealth of Massachusetts, on this 13th day of February, 2025.

     

    BLUEPRINT MEDICINES CORPORATION

     

     

     

     

    By:

    /s/ Kathryn Haviland​ ​

     

     

    Kathryn Haviland

     

     

    President and Chief Executive Officer

    ​

    POWER OF ATTORNEY AND SIGNATURES

    We, the undersigned officers and directors of Blueprint Medicines Corporation, hereby severally constitute and appoint Kathryn Haviland and Michael Landsittel, and each of them singly, our true and lawful attorneys with full power to any of them, and to each of them singly, to sign for us and in our names in the capacities indicated below the Registration Statement on Form S-8 filed herewith and any and all amendments to said Registration Statement, and generally to do all such things in our name and on our behalf in our capacities as officers and directors to enable Blueprint Medicines Corporation to comply with the provisions of the Securities Act of 1933, as amended, and all requirements of the Securities and Exchange Commission, hereby ratifying and confirming our signatures as they may be signed by our said attorneys, or any of them, to said registration statement and any and all amendments thereto.

    Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

    ​

    ​

    ​

    Signature

    ​

    Title

    ​

    Date

    ​

    ​

    ​

    ​

    ​

    /s/ Kathryn Haviland

    ​

    President, Chief Executive Officer and Director

    ​

    February 13, 2025

    Kathryn Haviland

    ​

    (Principal Executive Officer)

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    /s/ Michael Landsittel

    ​

    Chief Financial Officer

    ​

    February 13, 2025

    Michael Landsittel

    ​

    (Principal Financial Officer)

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    /s/ Ariel Hurley

    ​

    Vice President, Finance and Controller

    ​

    February 13, 2025

    Ariel Hurley

    ​

    (Principal Accounting Officer)

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    /s/ Jeffery W. Albers

    ​

    Chairman of the Board

    ​

    February 13, 2025

    Daniel S. Lynch

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    /s/ Daniella Beckman

    ​

    Director

    ​

    February 13, 2025

    Daniella Beckman

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    /s/ Alexis Borisy

    ​

    Director

    ​

    February 13, 2025

    Alexis Borisy

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    /s/ Lonnel Coats

    ​

    Director

    ​

    February 13, 2025

    Lonnel Coats

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    /s/ Habib Dable

    ​

    Director

    ​

    February 13, 2025

    Habib Dable

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    /s/ Mark Goldberg

    ​

    Director

    ​

    February 13, 2025

    Mark Goldberg, M.D.

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    /s/ Nicholas Lyndon

    ​

    Director

    ​

    February 13, 2025

    Nicholas Lyndon, Ph.D.

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    /s/ Lynn Seely

    ​

    Director

    ​

    February 13, 2025

    Lynn Seely, M.D.

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    /s/ John Tsai

    ​

    Director

    ​

    February 13, 2025

    John Tsai, M.D.

    ​

    ​

    ​


    Get the next $BPMC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BPMC

    DatePrice TargetRatingAnalyst
    3/20/2025$100.00Equal-Weight
    Morgan Stanley
    3/18/2025Outperform
    Wolfe Research
    3/17/2025$135.00Buy
    Jefferies
    3/7/2025$150.00Sector Outperform
    Scotiabank
    11/14/2024$126.00Overweight
    JP Morgan
    10/24/2024$88.00Neutral
    UBS
    5/14/2024$140.00Overweight
    Stephens
    5/6/2024$50.00 → $97.00Underperform → Market Perform
    Leerink Partners
    More analyst ratings

    $BPMC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Morgan Stanley resumed coverage on Blueprint Medicines with a new price target

      Morgan Stanley resumed coverage of Blueprint Medicines with a rating of Equal-Weight and set a new price target of $100.00

      3/20/25 7:59:08 AM ET
      $BPMC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wolfe Research initiated coverage on Blueprint Medicines

      Wolfe Research initiated coverage of Blueprint Medicines with a rating of Outperform

      3/18/25 7:49:08 AM ET
      $BPMC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jefferies initiated coverage on Blueprint Medicines with a new price target

      Jefferies initiated coverage of Blueprint Medicines with a rating of Buy and set a new price target of $135.00

      3/17/25 7:24:14 AM ET
      $BPMC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BPMC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CHIEF OPERATING OFFICER Rossi Christina sold $231,386 worth of shares (2,274 units at $101.75), decreasing direct ownership by 3% to 66,992 units (SEC Form 4)

      4 - Blueprint Medicines Corp (0001597264) (Issuer)

      5/7/25 4:32:25 PM ET
      $BPMC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PRINCIPAL ACCOUNTING OFFICER Hurley Ariel exercised 2,752 shares at a strike of $54.13 and sold $283,819 worth of shares (2,752 units at $103.13) (SEC Form 4)

      4 - Blueprint Medicines Corp (0001597264) (Issuer)

      5/7/25 4:30:51 PM ET
      $BPMC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CHIEF EXECUTIVE OFFICER Haviland Kate sold $216,461 worth of shares (2,498 units at $86.65), decreasing direct ownership by 1% to 165,929 units (SEC Form 4)

      4 - Blueprint Medicines Corp (0001597264) (Issuer)

      4/3/25 4:30:32 PM ET
      $BPMC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BPMC
    SEC Filings

    See more
    • SEC Form 10-Q filed by Blueprint Medicines Corporation

      10-Q - Blueprint Medicines Corp (0001597264) (Filer)

      5/1/25 4:19:40 PM ET
      $BPMC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Blueprint Medicines Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Blueprint Medicines Corp (0001597264) (Filer)

      5/1/25 7:12:39 AM ET
      $BPMC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Blueprint Medicines Corporation

      DEFA14A - Blueprint Medicines Corp (0001597264) (Filer)

      4/24/25 4:20:51 PM ET
      $BPMC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BPMC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Blueprint Medicines Corporation

      SC 13G/A - Blueprint Medicines Corp (0001597264) (Subject)

      11/14/24 1:22:36 PM ET
      $BPMC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Blueprint Medicines Corporation (Amendment)

      SC 13G/A - Blueprint Medicines Corp (0001597264) (Subject)

      4/10/24 12:58:49 PM ET
      $BPMC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Blueprint Medicines Corporation (Amendment)

      SC 13G/A - Blueprint Medicines Corp (0001597264) (Subject)

      2/14/24 10:03:02 AM ET
      $BPMC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BPMC
    Leadership Updates

    Live Leadership Updates

    See more
    • Blueprint Medicines Submits Supplemental New Drug Application to FDA for AYVAKIT® (avapritinib) for the Treatment of Indolent Systemic Mastocytosis

      -- Company to present registrational PIONEER trial results at 2023 AAAAI Annual Meeting -- CAMBRIDGE, Mass., Nov. 22, 2022 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced the submission of a supplemental new drug application to the U.S. Food and Drug Administration (FDA) for AYVAKIT® (avapritinib) for the treatment of adults with indolent systemic mastocytosis (SM). AYVAKIT was designed to potently and selectively inhibit D816V mutant KIT, the underlying cause of SM in about 95 percent of cases. The submission includes data from the registrationa

      11/22/22 4:36:00 PM ET
      $BPMC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Guardant Health and Blueprint Medicines present real-world data identifying EGFR C797X mutation as most common resistance mechanism to osimertinib therapy at IASLC 2022 World Conference on Lung Cancer

      Analysis utilizing GuardantINFORM™ real-world evidence platform shows cumulative incidence of EGFR C797X mutation was 12.5 percent in NSCLC patients likely to progress after first-line osimertinib treatment Study demonstrates need to identify C797X-driven resistance and tailor therapy options appropriately for patients with EGFR-mutant NSCLC Guardant Health Inc. (NASDAQ:GH), a leading precision oncology company, and Blueprint Medicines Corporation (NASDAQ:BPMC) announced today they are presenting new data demonstrating that the EGFR C797X mutation is the most common resistance mechanism to osimertinib therapy for patients with advanced non-small cell lung cancer (NSCLC). The results ar

      8/8/22 6:15:00 AM ET
      $BPMC
      $GH
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical Specialities
    • Blueprint Medicines Publishes Inaugural Corporate Responsibility Report

      -- Report highlights efforts to deliver sustainable value to patients and communities, foster a diverse and empowered workforce, and operate with exceptional integrity -- CAMBRIDGE, Mass., July 14, 2022 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC) today published its first Corporate Responsibility Report, highlighting its long-standing commitment to deliver sustainable value to patients with cancer and blood disorders, as well as the communities in which it operates. The report, which formalizes the company's efforts to track and report environmental, social and governance (ESG) standards and initiatives, includes summaries and performance metrics that demonstrate its purpos

      7/14/22 4:15:00 PM ET
      $BPMC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BPMC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Blueprint Medicines Reports First Quarter 2025 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance

      -- Achieved 61% year-over-year growth with $149.4 million in AYVAKIT net product revenues in the first quarter 2025 -- -- Raising AYVAKIT net product revenue guidance to $700 - $720 million for 2025 -- --  Initiated BLU-808 proof of concept studies in allergic rhinoconjunctivitis and chronic urticaria – CAMBRIDGE, Mass., May 1, 2025 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC) today reported financial results, provided a business update for the first quarter ended March 31, 2025, and provided corporate updates. "Blueprint Medicines strives to be a top-tier s

      5/1/25 7:00:00 AM ET
      $BPMC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Blueprint Medicines to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025

      CAMBRIDGE, Mass., April 25, 2025 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, May 1, 2025, to report its first quarter 2025 financial results and provide a corporate update. To access the live conference call, please dial 833-470-1428 (domestic) or 404-975-4839 (international) and refer to conference ID 082088. A webcast of the call will also be available under "Events and Presentations" in the Investors & Media section of the Blueprint Medicines website at http:/

      4/25/25 8:00:00 AM ET
      $BPMC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Blueprint Medicines to Present at 24th Annual Needham Virtual Healthcare Conference

      CAMBRIDGE, Mass., March 31, 2025 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC) today announced that company management will participate virtually in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Monday, April 7, 2025, at 12:45 p.m. ET. A live webcast of the presentation will be available by visiting the Investors & Media section of Blueprint Medicines' website at http://ir.blueprintmedicines.com. A replay of the webcast will be archived on Blueprint Medicines' website for 30 days following the presentation. About Blueprint Medicine

      3/31/25 8:00:00 AM ET
      $BPMC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BPMC
    Financials

    Live finance-specific insights

    See more
    • Blueprint Medicines Reports First Quarter 2025 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance

      -- Achieved 61% year-over-year growth with $149.4 million in AYVAKIT net product revenues in the first quarter 2025 -- -- Raising AYVAKIT net product revenue guidance to $700 - $720 million for 2025 -- --  Initiated BLU-808 proof of concept studies in allergic rhinoconjunctivitis and chronic urticaria – CAMBRIDGE, Mass., May 1, 2025 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC) today reported financial results, provided a business update for the first quarter ended March 31, 2025, and provided corporate updates. "Blueprint Medicines strives to be a top-tier s

      5/1/25 7:00:00 AM ET
      $BPMC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Blueprint Medicines to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025

      CAMBRIDGE, Mass., April 25, 2025 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, May 1, 2025, to report its first quarter 2025 financial results and provide a corporate update. To access the live conference call, please dial 833-470-1428 (domestic) or 404-975-4839 (international) and refer to conference ID 082088. A webcast of the call will also be available under "Events and Presentations" in the Investors & Media section of the Blueprint Medicines website at http:/

      4/25/25 8:00:00 AM ET
      $BPMC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Blueprint Medicines Reports Fourth Quarter and Full Year 2024 Results

      -- Achieved $479.0 million in AYVAKIT® (avapritinib) global net product revenues in 2024, including $144.1 million in the fourth quarter -- -- Anticipate global AYVAKIT net product revenue of approximately $680 million to $710 million in 2025, representing 45% percent year-over-year growth at the midpoint -- -- Peak systemic mastocytosis franchise revenue opportunity updated to $4 billion, with AYVAKIT expected to achieve $2 billion in revenue by 2030 -- -- AYVAKIT 3-year safety and efficacy results in ISM and BLU-808 healthy volunteer data among 14 total abstracts accepted for presentation at 2025 AAAAI / WAO Joint Congress -- CAMBRIDGE, Mass., Feb. 13, 2025 /PRNewswire/ -- Blueprint Medici

      2/13/25 7:00:00 AM ET
      $BPMC
      Biotechnology: Pharmaceutical Preparations
      Health Care